⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536539 | 1.00 | — | — | |
| Boric Acid SCHEMBL22439653 | 0.92 | AURKA (0.45) | — | |
| SCHEMBL20678836 | 0.85 | — | — | |
| SCHEMBL14354842 | 0.81 | ALDH1A1 (0.41) | — | |
| SCHEMBL1807075 | 0.81 | CLK4 (0.47) | — | |
| SCHEMBL1340918 | 0.81 | ALDH1A1 (0.53) | — | |
| SCHEMBL2713912 | 0.81 | S100A4 (0.49) | — | |
| SCHEMBL25898415 | 0.79 | — | — | |
| SCHEMBL1647418 | 0.78 | ALDH1A1 (0.50) | — | |
| SCHEMBL30561232 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 752 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836111-A | Continuous synthesis method of fluoropyridine | 峰成医药科技(天津)有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-110964011-B | Synthetic method of 8-chloro-1, 7-naphthyridine-3-formaldehyde | 诚达药业股份有限公司 | 2022-06-21 | — | — | CN | claimed |
| CN-109748903-B | Preparation method of pyrifazimine | 北京协和制药二厂 | 2021-08-10 | — | — | CN | claimed |
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | claimed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | claimed |
| EP-2321316-B1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-03-12 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |
| EP-4727944-A1 | [1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES USEFUL AS A MEDICAMENT | Perha Pharmaceuticals (FR) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720060-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2026-04-08 | — | — | EP | disclosed |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| WO-1993008186-A1 | PYRIDINE-3-CARBOXYLIC ACID ESTERS OR AMIDES USEFUL AS 5-HT3 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-04-29 | — | — | WO | disclosed |
| EP-0255297-B1 | AZABICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | BEECHAM GROUP PLC (GB) | 1993-04-21 | — | — | EP | disclosed |
| US-4808588-A | HEADACHES, CENTRAL NERVOUS SYSTEM DISORDERS, ANTIARRHYTHMIA ANTIEMETIC AGENTS | BEECHAM GROUP, P.L.C. (GB) | 1989-02-28 | — | — | US | disclosed |
| EP-0255297-A2 | Azabicyclic compounds, process for their preparation, and their pharmaceutical use | BEECHAM GROUP PLC (GB) | 1988-02-03 | — | — | EP | disclosed |